Perioperative dry eye, including cataract, retinal diseases, and refractive surgery.
Conditions
Interventions
Control group:Conventional treatment
Experimental group:Conventional treatment 0.05% Cyclosporine Eye Drops II
Sponsors
Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University)
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. >=18 years of age; 2. patients meet the indications for eye-related surgery. 3. Voluntarily participate in this study and sign the informed consent form, and can cooperate to complete the examination and 3-month treatment and follow-up. If the subject is unable to read and sign the informed consent form due to incapacitation or other reasons, his/her guardian should act on behalf of the informed process and sign the informed consent form. 4. 1 week after surgery, the diagnostic criteria for dry eye in the ‘Chinese Expert Consensus on the Clinical Diagnosis and Treatment of Dry Eye (2024)’ were met: FBUT = 5 s or Schirmer ? <= 5 mm/5 min without surface anaesthesia, and one of the subjective symptoms such as dryness, foreign body sensation, burning sensation, fatigue, discomfort, and fluctuation of visual acuity in the eye, could be diagnosed as dry eye. Dry eye was diagnosed with 5 s< FBUT<=10 s or 5 mm/5 min under no surface anaesthesia< Schirmer ?<=10 mm/5 min, with one of the subjective symptoms such as dryness, foreign body sensation, burning sensation, fatigue, discomfort, and fluctuation of vision in the eye, as well as positive fluorescein staining of the cornea and conjunctiva. 5. Inclusion of surgical methods: cataract patients with cataract ultrasonic emulsification surgery; refractive patients with FS-LASIK (half femtosecond) surgery or SMILE full femtosecond surgery; patients with fundus disease with vitrectomy surgery or vitreous injection surgery.
Exclusion criteria
Exclusion criteria: 1.Patients who have undergone eye surgery or experienced eye trauma within six months prior to the baseline examination; 2.Patients with a history of intraocular inflammation within six months prior to the baseline examination; 3.Patients with other microbial infections of the eyeball and its appendages; 4.Patients with eyelid abnormalities (such as entropion, ectropion, tumors, edema, eyelid spasms, incomplete eyelid closure, trichiasis, ptosis, eyelid laxity, etc.); 5.Patients who are simultaneously participating in clinical trials of other ophthalmic drugs or medical devices. 6.Patients with severe primary diseases affecting the liver, kidneys, and hematopoietic system, as well as those with mental disorders; 7.Use of hormones, nonsteroidal anti-inflammatory drugs, immunosuppressants, cholinergic drugs, or other medications that may affect the study due to other diseases within 3 months prior to surgery. 8.Allergic to 0.05% cyclosporine eye drops; 9.Pregnant or breastfeeding women;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tear Film Breakup Time (BUT); | — |
Secondary
| Measure | Time frame |
|---|---|
| Ocular Surface Disease Index (OSDI) Score; | — |
Countries
China
Contacts
Public ContactHu liu
Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University)
Outcome results
None listed